Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice.
The mucopolysaccharidoses (MPSs) are lysosomal storage diseases resulting from impaired catabolism of sulfated glycosaminoglycans. MPS VII mice lack lysosomal beta-glucuronidase (GUSB) activity, leading to the accumulation of partially degraded chondroitin, dermatan, and heparan sulfates in most tissues. Consequently, these mice develop most of the symptoms exhibited by human MPS VII patients, including progressive visual and cognitive deficits. To investigate the effects of reducing lysosomal storage in nervous tissues, we injected recombinant adeno-associated virus encoding GUSB directly into the vitreous humor of young adult mice. Interestingly, GUSB activity was subsequently detected in the brains of the recipients. At 8-12 weeks after treatment, increased GUSB activity and reduced lysosomal distension were found in regions of the thalamus and tectum that received inputs from the injected eye. Lysosomal storage was also reduced in adjacent nonvisual regions, including the hippocampus, as well as in the visual cortex. The findings suggest that both diffusion and trans-synaptic transfer contribute to the dissemination of enzyme activity within the CNS. Intravitreal injection may thus provide a means of delivering certain therapeutic gene products to specific areas within the CNS.
Hennig
Anne K
AK
Department of Internal Medicine, Division of Stem Cell Biology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Levy
Beth
B
Ogilvie
Judith Mosinger
JM
Vogler
Carole A
CA
Galvin
Nancy
N
Bassnett
Steven
S
Sands
Mark S
MS
D000818:Animals; D002490:Central Nervous System / Q000201:enzymology* / Q000473:pathology / Q000821:virology; D004279:DNA, Viral / Q000032:analysis; D000229:Dependovirus / Q000235:genetics; D004195:Disease Models, Animal; D004333:Drug Administration Routes; D004789:Enzyme Activation / Q000235:genetics; D005123:Eye / Q000201:enzymology / Q000821:virology; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D005966:Glucuronidase / Q000096:biosynthesis / Q000172:deficiency / Q000235:genetics*; D006624:Hippocampus / Q000201:enzymology / Q000473:pathology / Q000821:virology; D006801:Humans; D008247:Lysosomes / Q000201:enzymology* / Q000473:pathology; D051379:Mice; D008818:Mice, Neurologic Mutants; D016538:Mucopolysaccharidosis VII / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D016133:Polymerase Chain Reaction; D013477:Superior Colliculi / Q000201:enzymology / Q000473:pathology / Q000821:virology; D013788:Thalamus / Q000201:enzymology / Q000473:pathology / Q000821:virology; D016896:Treatment Outcome; D014793:Visual Cortex / Q000201:enzymology / Q000473:pathology / Q000821:virology; D014795:Visual Pathways / Q000201:enzymology / Q000473:pathology / Q000821:virology
D004279:DNA, Viral; D005966:Glucuronidase